Erasca partners with Merck for cancer drug combination trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. GOOG
6. CSX
7. IBM
8. KNX
9. AMD
10. INTC

Go back to Erasca partners with Merck for cancer drug combination trial
(NASDAQ: ERAS) Delayed: 19.34 -0.17 (0.87%)
Previous Close $19.51    52 Week High $ 
Open $19.03    52 Week Low $ 
Day High $19.65    P/E N/A 
Day Low $18.60    EPS $ 
Volume 2,318,085